Abstract
Ligand-independent and/or proNGF-induced p75NTR signaling has emerged as a potential major contributor to a number of pathological states, including axotomy-induced death, motor neuron degeneration, neuronal degeneration in Alzheimers disease and oligodendrocyte death following spinal cord injury. A long standing goal in the neurotrophin field has been the development of non-peptide, small molecules capable of functioning as specific ligands at neurotrophin receptors such as p75NTR to promote desired biological outcomes. Synthetic peptides modeled on neurotrophin protein domains have been found to bind to and activate various neurotrophin receptors, raising the possibility that active, nonpeptide, small molecule ligands might also be identified; however, traditional high-throughput screening approaches have been largely ineffective in identifying such compounds. Using pharmacophores derived from the structure of loop 1 of nerve growth factor, non-peptide, small molecules that function as p75NTR ligands to promote survival and block proNGFinduced death have recently been identified. Small molecule p75NTR ligands, with high potency and specificity, may provide novel therapeutic approaches for neurodegenerative diseases, neurotrauma and other pathologic states.
CNS & Neurological Disorders - Drug Targets
Title: Small Molecule Modulation of p75 Neurotrophin Receptor Functions
Volume: 7 Issue: 1
Author(s): Frank M. Longo, Frank M. Longo, Stephen M. Massa and Stephen M. Massa
Affiliation:
Abstract: Ligand-independent and/or proNGF-induced p75NTR signaling has emerged as a potential major contributor to a number of pathological states, including axotomy-induced death, motor neuron degeneration, neuronal degeneration in Alzheimers disease and oligodendrocyte death following spinal cord injury. A long standing goal in the neurotrophin field has been the development of non-peptide, small molecules capable of functioning as specific ligands at neurotrophin receptors such as p75NTR to promote desired biological outcomes. Synthetic peptides modeled on neurotrophin protein domains have been found to bind to and activate various neurotrophin receptors, raising the possibility that active, nonpeptide, small molecule ligands might also be identified; however, traditional high-throughput screening approaches have been largely ineffective in identifying such compounds. Using pharmacophores derived from the structure of loop 1 of nerve growth factor, non-peptide, small molecules that function as p75NTR ligands to promote survival and block proNGFinduced death have recently been identified. Small molecule p75NTR ligands, with high potency and specificity, may provide novel therapeutic approaches for neurodegenerative diseases, neurotrauma and other pathologic states.
Export Options
About this article
Cite this article as:
Longo M. Frank, Longo M. Frank, Massa M. Stephen and Massa M. Stephen, Small Molecule Modulation of p75 Neurotrophin Receptor Functions, CNS & Neurological Disorders - Drug Targets 2008; 7 (1) . https://dx.doi.org/10.2174/187152708783885093
DOI https://dx.doi.org/10.2174/187152708783885093 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) The Association between Regular Cannabis Exposure and Alterations of Human Brain Morphology: An Updated Review of the Literature
Current Pharmaceutical Design Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy Motor and Sensory Dysfunction in Musician's Dystonia
Current Neuropharmacology Current Perspectives on the Therapeutic Utility of VR1 Antagonists
Current Medicinal Chemistry Omega-3 Nutrition Therapy for the Treatment of Diabetic Sensorimotor Polyneuropathy
Current Diabetes Reviews Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry Neuropeptides as Possible Targets in Sleep Disorders: Special Emphasis on Hypocretin-Deficient Narcolepsy
CNS & Neurological Disorders - Drug Targets A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Rationale for Development of New Oral Anticoagulants
Cardiovascular & Hematological Disorders-Drug Targets Oxidized Galectin-1 is an Essential Factor for Peripheral Nerve Regeneration
Current Drug Targets Wii-Workouts on Chronic Pain, Physical Capabilities and Mood of Older Women: A Randomized Controlled Double Blind Trial
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Neuropharmacology New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Schwann Cell Transplantation for CNS Repair
Current Medicinal Chemistry Antioxidative Peptides: Trends and Perspectives for Future Research
Current Medicinal Chemistry Comparative Neurophysiologic Study of Pain in Patients with Parkinson's Disease and Patients with Persistent Pain After Spinal Surgery
Neuroscience and Biomedical Engineering (Discontinued)